- 英名:Vandetanib
- 商品名:カプレルサ錠100mg(サノフィ株式会社)
- 動物を用いた試験でバンデタニブを持続注入したところ、注射部位に炎症が認められたため、ヒトにバンデタニブを静脈内投与する試験は実施していない(2.7.1 生物薬剤学試験及び関連する分析法 p.13)
- バンデタニブの曝露量は食事による影響を受けない(2.7.1 生物薬剤学試験及び関連する分析法 p.7,p.22)
- 血漿中の主代謝物は N-脱メチル体であった(2.7.2 臨床薬理試験 p.11)
- N-脱メチル体はバンデタニブと同様の VEGF 酵素阻害作用及び VEGF 刺激による増殖の阻害作用と選択性を示した
- N-脱メチル体の曝露量はバンデタニブの値に対して約 14.1%
- 軽度又は中等度腎機能障害者では、腎機能が正常な健康被験者に比べ、バンデタニブの曝露量は 1.46 倍(軽度)及び 1.62 倍(中等度)(2.7.2 臨床薬理試験 p.11)
- 軽度腎機能障害:開始用量を調節する必要なし
- 中等度(30 mL/min 以上 50 mL/min 未満):6 例中 5 例(83%)で QT 延長等の有害事象のためバンデタニブを 200 mg に減量
- 重度腎機能障害者(CrCL:30 mL/min 未満):曝露量が約 2 倍以上に増加する可能性、投与推奨されない
- 重度腎機能障害者における非結合型バンデタニブの AUC は、健康被験者の 2 倍以上である可能性(2.7.2 臨床薬理試験 p.45)
- Mol Cancer Ther. 2008 Sep;7(9):3006-17. doi: 10.1158/1535-7163.MCT-08-0370.
- Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
- PMID: 18790781 https://www.ncbi.nlm.nih.gov/pubmed/18790781
- Invest New Drugs. 2009 Jun;27(3):253-61. doi: 10.1007/s10637-008-9182-8. Epub 2008 Nov 11.
- Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
- PMID: 19002384 https://www.ncbi.nlm.nih.gov/pubmed/19002384
- Clin Pharmacokinet. 2010 Sep;49(9):607-18. doi: 10.2165/11534330-000000000-00000.
- Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
- PMID: 20690783 https://www.ncbi.nlm.nih.gov/pubmed/20690783
- J Thorac Oncol. 2010 Aug;5(8):1285-8. doi: 10.1097/JTO.0b013e3181e3a2d1.
- A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
- PMID: 20661087 https://www.ncbi.nlm.nih.gov/pubmed/20661087
- Clin Ther. 2011 Mar;33(3):315-27. doi: 10.1016/j.clinthera.2011.04.005.
- Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
- PMID: 21600385 https://www.ncbi.nlm.nih.gov/pubmed/21600385
- Drugs R D. 2011;11(1):37-51. doi: 10.2165/11586980-000000000-00000.
- Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
- PMID: 21410294 https://www.ncbi.nlm.nih.gov/pubmed/21410294
- Clin Ther. 2012 Jan;34(1):221-37. doi: 10.1016/j.clinthera.2011.11.011. Epub 2011 Dec 28.
- Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
- PMID: 22206795 https://www.ncbi.nlm.nih.gov/pubmed/22206795
- Clin Cancer Res. 2013 Jun 1;19(11):3050-8. doi: 10.1158/1078-0432.CCR-13-0306. Epub 2013 Mar 27.
- Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
- PMID: 23536435 https://www.ncbi.nlm.nih.gov/pubmed/23536435
- Eur J Drug Metab Pharmacokinet. 2013 Sep;38(3):149-57. doi: 10.1007/s13318-013-0123-3. Epub 2013 Feb 28.
- Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.
- PMID: 23446814 https://www.ncbi.nlm.nih.gov/pubmed/23446814
- Clin Pharmacokinet. 2014 Sep;53(9):837-47. doi: 10.1007/s40262-014-0161-2.
- Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
- PMID: 25117183 https://www.ncbi.nlm.nih.gov/pubmed/25117183
- J Cancer Res Ther. 2014 Jan-Mar;10(1):84-8. doi: 10.4103/0973-1482.131393.
- Validation of a high-performance liquid chromatographic ultraviolet detection method for the quantification of vandetanib in rat plasma and its application to pharmacokinetic studies.
- PMID: 24762492 https://www.ncbi.nlm.nih.gov/pubmed/24762492
- Endocr Pract. 2016 Nov 7. [Epub ahead of print]
- SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
- PMID: 27819766 https://www.ncbi.nlm.nih.gov/pubmed/27819766
コメントをかく